VKH
SUPN icon

Virtu KCG Holdings’s Supernus Pharmaceuticals SUPN Stock Holding History

Virtu KCG Holdings’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8,056
Closed -$252K – 3475
2017
Q1 		$252K Buy
+8,056
New +$216K 0.01% 2157

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Virtu KCG Holdings's SUPN Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 8,056 shares — an estimated $252K sold.

Virtu KCG Holdings first reported a position in SUPN in Q1 2017 and held it in 1 quarter. The position peaked at $252K in Q1 2017. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 8,056 Supernus Pharmaceuticals shares in Q2 2017, an estimated $252K.
  • Virtu KCG Holdings first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Virtu KCG Holdings's Supernus Pharmaceuticals position peaked at $252K in Q1 2017.
  • 265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.